CSCI Research Brief

Cannabinoids for The Treatment of Ulcerative Colitis (UC) and Crohn’s Disease (CD)

Tartakover Matalon S, Azar S, Meiri D, et al. Endocannabinoid levels in ulcerative colitis patients correlate with clinical parameters and are affected by cannabis consumption. Front Endocrinol. 2021;12:685289. doi: 10.3389/fendo.2021.685289 

Inflammatory bowel disease (IBD) includes two inflammatory, chronic, idiopathic GI disorders. IBD may present as ulcerative colitis (UC) or Crohn’s disease (CD). This study examined the effects of cannabinoids on symptoms of IBS, including the patients’ quality of life.

The endocannabinoid system (ECS) is thought to play a role in the development of IBD. This study involved taking blood samples and biopsies from study participants with IBD to determine the effect of CBD and THC and endocannabinoids (i.e., molecules like CBD and THC made in the body) on symptoms.

Study Findings

Thirteen Chrone’s disease (CD), and 9 ulcerative colitis (UC) patients were treated with phytocannabinoids (i.e., plant-based cannabinoids) such as delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Another group of patients with UC and CD were given a placebo.

The symptoms of ulcerative colitis negatively impact the quality of life in patients with IBS. In UC, for example, symptoms include diarrhea, urgency, and frequent bowel movements, rectal bleeding, and fatigue. In the study, the reduction in bowel movements was associated with changes in circulating endocannabinoids. There was a positive correlation between 2-AG (i.e., endocannabinoid) levels and quality of life improvement.

CD patients received CBD/THC oil containing 160/40 mg/ml or a placebo. Compared with the placebo group, the cannabis group exhibited a significantly improved Crohn’s disease activity index (CDAI) and quality of life (QOL) index.


IBS patients may benefit from cannabis use because phytocannabinoids, such as cannabidiol (CBD), alter the endocannabinoid “tone” (i.e., the ECS’s overall functioning) and may alleviate some IBD symptoms.

Link to study:  

General Disclaimer

Center for Scientific Cannabinoid Information (CSCI) has placed information, including links to other websites or content belonging to or originating from third parties, on this website as a service to the general public and for general informational and educational purposes only.  The information on this website is not intended to substitute particularized advice of specialists or qualified professionals.  No content on this website should ever be used as a substitute for direct advice from appropriate professionals or qualified specialists.  This website could include inaccuracies or typographical errors.  The materials on this website do not constitute medical advice, do not necessarily reflect the opinions of CSCI or any of its employees, agents, affiliates, or subsidiaries, and are not guaranteed to be correct, complete, or up‐to‐date.  The publications, articles, and information on this website are provided as is without warranty of any kind, either express or implied, regarding accuracy, adequacy, validity, reliability, availability, or completeness, and CSCI does not warrant, endorse, guarantee, or assume responsibility for the accuracy or reliability of any information included on this website from third-party websites linked through this website.  UNDER NO CIRCUMSTANCE SHALL CSCI HAVE ANY LIABILITY TO YOU FOR ANY LOSS OR DAMAGE OF ANY KIND INCURRED AS A RESULT OF THE USE OF THE INFORMATION CONTAINED ON THIS WEBSITE OR RELIANCE ON ANY SUCH INFORMATION PROVIDED ON THIS WEBSITE. YOUR USE OF THIS WEBSITE AND YOUR RELIANCE ON ANY INFORMATION ON THIS WEBSITE IS SOLELY AT YOUR OWN RISK.

You cannot copy content of this page